Selected research
Industry Research
Rebamipide Industry Research Report 2026
Market perspective
The global Rebamipide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Rebamipide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Rebamipide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Rebamipide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Rebamipide include Yuanlijian Pharmaceutical, Dong Wha Pharm, Suzhou Tianma Pharmaceutical Group, Cheer Fine Pharmaceutical, Menovo, Pfizer, Otsuka Pharmaceutical, Strides Pharma Science and Saurav Chemicals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Rebamipide market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rebamipide Market by Company
Yuanlijian Pharmaceutical
Dong Wha Pharm
Suzhou Tianma Pharmaceutical Group
Cheer Fine Pharmaceutical
Menovo
Pfizer
Otsuka Pharmaceutical
Strides Pharma Science
Saurav Chemicals
SAMOH Pharm
Macleods Pharma
Kyung Dong Pharm
Anlon Healthcare Pvt Ltd
Rebamipide Segment by Type
Pharmacy
Capsule
Rebamipide Segment by Application
Pharmacy
Hospital
Others
Rebamipide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rebamipide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rebamipide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rebamipide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rebamipide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rebamipide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rebamipide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pharmacy
- Capsule
Applications
- Pharmacy
- Hospital
- Others
Companies covered
- Yuanlijian Pharmaceutical
- Dong Wha Pharm
- Suzhou Tianma Pharmaceutical Group
- Cheer Fine Pharmaceutical
- Menovo
- Pfizer
- Otsuka Pharmaceutical
- Strides Pharma Science
- Saurav Chemicals
- SAMOH Pharm
- Macleods Pharma
- Kyung Dong Pharm
- Anlon Healthcare Pvt Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rebamipide Market Size (2021-2032)
- 2.2.2 Global Rebamipide Sales (2021-2032)
- 2.2.3 Global Rebamipide Market Average Price (2021-2032)
- 2.3 Rebamipide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pharmacy
- 2.3.3 Capsule
- 2.4 Rebamipide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharmacy
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rebamipide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Rebamipide Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Rebamipide Revenue of Manufacturers (2021-2026)
- 3.4 Global Rebamipide Average Price by Manufacturers (2021-2026)
- 3.5 Global Rebamipide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Rebamipide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rebamipide, Product Type & Application
- 3.8 Global Manufacturers of Rebamipide, Established Date
- 3.9 Global Rebamipide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yuanlijian Pharmaceutical
- 4.1.1 Yuanlijian Pharmaceutical Company Information
- 4.1.2 Yuanlijian Pharmaceutical Business Overview
- 4.1.3 Yuanlijian Pharmaceutical Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yuanlijian Pharmaceutical Rebamipide Product Portfolio
- 4.1.5 Yuanlijian Pharmaceutical Recent Developments
- 4.2 Dong Wha Pharm
- 4.2.1 Dong Wha Pharm Company Information
- 4.2.2 Dong Wha Pharm Business Overview
- 4.2.3 Dong Wha Pharm Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Dong Wha Pharm Rebamipide Product Portfolio
- 4.2.5 Dong Wha Pharm Recent Developments
- 4.3 Suzhou Tianma Pharmaceutical Group
- 4.3.1 Suzhou Tianma Pharmaceutical Group Company Information
- 4.3.2 Suzhou Tianma Pharmaceutical Group Business Overview
- 4.3.3 Suzhou Tianma Pharmaceutical Group Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Suzhou Tianma Pharmaceutical Group Rebamipide Product Portfolio
- 4.3.5 Suzhou Tianma Pharmaceutical Group Recent Developments
- 4.4 Cheer Fine Pharmaceutical
- 4.4.1 Cheer Fine Pharmaceutical Company Information
- 4.4.2 Cheer Fine Pharmaceutical Business Overview
- 4.4.3 Cheer Fine Pharmaceutical Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Cheer Fine Pharmaceutical Rebamipide Product Portfolio
- 4.4.5 Cheer Fine Pharmaceutical Recent Developments
- 4.5 Menovo
- 4.5.1 Menovo Company Information
- 4.5.2 Menovo Business Overview
- 4.5.3 Menovo Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Menovo Rebamipide Product Portfolio
- 4.5.5 Menovo Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Rebamipide Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Otsuka Pharmaceutical
- 4.7.1 Otsuka Pharmaceutical Company Information
- 4.7.2 Otsuka Pharmaceutical Business Overview
- 4.7.3 Otsuka Pharmaceutical Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Otsuka Pharmaceutical Rebamipide Product Portfolio
- 4.7.5 Otsuka Pharmaceutical Recent Developments
- 4.8 Strides Pharma Science
- 4.8.1 Strides Pharma Science Company Information
- 4.8.2 Strides Pharma Science Business Overview
- 4.8.3 Strides Pharma Science Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Strides Pharma Science Rebamipide Product Portfolio
- 4.8.5 Strides Pharma Science Recent Developments
- 4.9 Saurav Chemicals
- 4.9.1 Saurav Chemicals Company Information
- 4.9.2 Saurav Chemicals Business Overview
- 4.9.3 Saurav Chemicals Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Saurav Chemicals Rebamipide Product Portfolio
- 4.9.5 Saurav Chemicals Recent Developments
- 4.10 SAMOH Pharm
- 4.10.1 SAMOH Pharm Company Information
- 4.10.2 SAMOH Pharm Business Overview
- 4.10.3 SAMOH Pharm Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 SAMOH Pharm Rebamipide Product Portfolio
- 4.10.5 SAMOH Pharm Recent Developments
- 4.11 Macleods Pharma
- 4.11.1 Macleods Pharma Company Information
- 4.11.2 Macleods Pharma Business Overview
- 4.11.3 Macleods Pharma Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Macleods Pharma Rebamipide Product Portfolio
- 4.11.5 Macleods Pharma Recent Developments
- 4.12 Kyung Dong Pharm
- 4.12.1 Kyung Dong Pharm Company Information
- 4.12.2 Kyung Dong Pharm Business Overview
- 4.12.3 Kyung Dong Pharm Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Kyung Dong Pharm Rebamipide Product Portfolio
- 4.12.5 Kyung Dong Pharm Recent Developments
- 4.13 Anlon Healthcare Pvt Ltd
- 4.13.1 Anlon Healthcare Pvt Ltd Company Information
- 4.13.2 Anlon Healthcare Pvt Ltd Business Overview
- 4.13.3 Anlon Healthcare Pvt Ltd Rebamipide Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Anlon Healthcare Pvt Ltd Rebamipide Product Portfolio
- 4.13.5 Anlon Healthcare Pvt Ltd Recent Developments
5 Global Rebamipide Market Scenario by Region
- 5.1 Global Rebamipide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Rebamipide Sales by Region: 2021-2032
- 5.2.1 Global Rebamipide Sales by Region: 2021-2026
- 5.2.2 Global Rebamipide Sales by Region: 2027-2032
- 5.3 Global Rebamipide Revenue by Region: 2021-2032
- 5.3.1 Global Rebamipide Revenue by Region: 2021-2026
- 5.3.2 Global Rebamipide Revenue by Region: 2027-2032
- 5.4 North America Rebamipide Market Facts & Figures by Country
- 5.4.1 North America Rebamipide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Rebamipide Sales by Country (2021-2032)
- 5.4.3 North America Rebamipide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Rebamipide Market Facts & Figures by Country
- 5.5.1 Europe Rebamipide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Rebamipide Sales by Country (2021-2032)
- 5.5.3 Europe Rebamipide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Rebamipide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rebamipide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Rebamipide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Rebamipide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rebamipide Market Facts & Figures by Country
- 5.7.1 South America Rebamipide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Rebamipide Sales by Country (2021-2032)
- 5.7.3 South America Rebamipide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Rebamipide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rebamipide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Rebamipide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Rebamipide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Rebamipide Sales by Type (2021-2032)
- 6.1.1 Global Rebamipide Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Rebamipide Sales Market Share by Type (2021-2032)
- 6.2 Global Rebamipide Revenue by Type (2021-2032)
- 6.2.1 Global Rebamipide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Rebamipide Revenue Market Share by Type (2021-2032)
- 6.3 Global Rebamipide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Rebamipide Sales by Application (2021-2032)
- 7.1.1 Global Rebamipide Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Rebamipide Sales Market Share by Application (2021-2032)
- 7.2 Global Rebamipide Revenue by Application (2021-2032)
- 7.2.1 Global Rebamipide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Rebamipide Revenue Market Share by Application (2021-2032)
- 7.3 Global Rebamipide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rebamipide Value Chain Analysis
- 8.1.1 Rebamipide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rebamipide Production Mode & Process
- 8.2 Rebamipide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rebamipide Distributors
- 8.2.3 Rebamipide Customers
9 Global Rebamipide Analyzing Market Dynamics
- 9.1 Rebamipide Industry Trends
- 9.2 Rebamipide Industry Drivers
- 9.3 Rebamipide Industry Opportunities and Challenges
- 9.4 Rebamipide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst